Kaplan–Meier estimates demonstrated that among women over age 50 with pT1‐2N0M0 HR+HER2‐BC and RS ≥26, those who received adjuvant CET had a significantly higher OS compared to patients who received ET alone, independent of T stage (p < 0.001, Figure 3). Here, ERBB2 is linked to breast cancer.